Abstract
More than 8000 people die of melanoma in the USA annually. Although early detection of melanoma results in a 5-year survival of up to 90–95%, those presenting at advanced stages have dismal prognoses due to ineffective systemic therapies. In general, patients with early melanoma can be successfully treated with local surgery. However, approximately 8–20% of lentigo maligna melanomas recur, leading to frequent re-excisions, cosmetic issues and, as a result, increased medical costs. An accurate evaluation of melanoma margins is important to prevent local tumor recurrence and progression to advanced stage disease. This review will discuss the role of clinically based noninvasive tools, histology, immunohistochemistry and molecular technologies in melanoma margin assessment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
